Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
New organ-threatening autoimmune disease
Proteinuric AKI, pulmonary haemorrhage, rapidly progressive ILD, myocarditis, severe cytopenia, focal neurological disease, vasculitic neuropathy or thrombosis means the previous undifferentiated label is no longer sufficient.
Action: Admit or assess urgently, stabilise the organ, obtain targeted serology, imaging, fluid or tissue and infection studies, and involve rheumatology with the relevant organ specialty before empirical treatment obscures diagnosis.
Synopsis
Use undifferentiated connective-tissue disease as a precise longitudinal diagnosis when autoimmune features are real but criteria remain incomplete, avoid treating incidental antibodies, monitor organ and pregnancy risk, and reclassify promptly when evidence evolves.
UCTD describes persistent clinical autoimmune features with supportive serology that do not meet a defined connective-tissue diagnosis after mimics are assessed; it is not a synonym for positive ANA.
Document objective features precisely: Raynaud pattern, swollen joints, ulcers, photosensitive rash, salivary or ocular measures, capillaries, strength, blood counts, urine and organ physiology.
ANA titre and pattern alter pre-test interpretation but do not measure activity; anti-Ro, anti-La, RNP, dsDNA, centromere, topoisomerase, myositis and antiphospholipid tests are chosen by phenotype.
Key red flags
New proteinuria, glomerular haematuria, hypertension or creatinine rise requires urgent renal assessment for lupus, vasculitis, TMA or another kidney disease.
Evolution toward lupus
New nephritic urine, anti-dsDNA, low complement, immune cytopenia or characteristic rash should trigger immediate SLE and nephritis reassessment.
Investigation priorities
01
Structured history and examinationFirst step
Establish whether symptoms represent objective systemic autoimmunity and create a reproducible baseline.
Management branches
First-line formulationProve autoimmunity without overcalling
Persistent systemic symptoms and an ANA result raise concern but no defined CTD is established.
Document objective inflammatory, vascular, glandular, skin and organ findings and review infections, medicines, thyroid disease, malignancy and non-inflammatory pain or fatigue.
Obtain baseline blood, renal and urine tests and phenotype-directed antibodies rather than a blanket panel; use capillaroscopy, PFT, imaging or biopsy only for a specific question.
Preferred mild managementTreat manifestations, not the label
Stable UCTD causes skin, joint, sicca or Raynaud symptoms without major-organ disease.
Key medicines
HydroxychloroquineFor persistent inflammatory skin or joint manifestations use 200–400 mg orally once daily, not exceeding 5 mg/kg actual body weight/day, and continue only when an agreed clinical benefit is demonstrated.
Nifedipine modified releaseFor troublesome Raynaud phenomenon start 30 mg orally once daily and increase, commonly to 60 mg once daily, according to response, blood pressure and product.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.